Aclaris Therapeutics Stock Surges 10.2% - What's Next?

Shares of the biotech company jump after a recent analyst report.

Apr. 1, 2026 at 6:19pm

Got story updates? Submit your updates here. ›

Shares of Aclaris Therapeutics (NASDAQ: ACRS) rose 10.2% on Wednesday, trading as high as $4.13 per share. The stock closed at $4.13, up from the previous close of $3.75. Trading volume was 649,372 shares, down 73% from the average daily volume of 2,374,709 shares.

Why it matters

The stock price increase comes after a recent analyst report on the company. Aclaris Therapeutics is a clinical-stage biotech focused on developing treatments for dermatological conditions and rare disorders. Investors will be watching to see if the stock can maintain its momentum and build on this latest surge.

The details

Several Wall Street analysts have weighed in on Aclaris Therapeutics recently. One firm downgraded the stock from 'hold' to 'sell', while others maintained 'buy' ratings with price targets ranging from $8 to $16. The company reported its latest quarterly results in late February, missing analyst estimates for revenue.

  • Aclaris Therapeutics' stock price jumped 10.2% on Wednesday, April 1, 2026.
  • The company reported its Q4 2025 financial results on February 26, 2026.

The players

Aclaris Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for dermatological conditions and rare disorders.

Wall Street Zen

A financial research firm that downgraded Aclaris Therapeutics from 'hold' to 'sell' in a recent report.

Wedbush

An investment firm that reiterated an 'outperform' rating and $8 price target on Aclaris Therapeutics.

HC Wainwright

An investment bank that reissued a 'buy' rating and $16 price target on Aclaris Therapeutics.

Craig Hallum

An investment firm that assumed coverage on Aclaris Therapeutics with a 'buy' rating and $10 price target.

Got photos? Submit your photos here. ›

What they’re saying

“Wall Street Zen cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th.”

— Wall Street Zen, Research Firm

“Wedbush reiterated an "outperform" rating and issued a $8.00 price target on shares of Aclaris Therapeutics in a report on Tuesday.”

— Wedbush, Investment Firm

“HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research report on Thursday, March 19th.”

— HC Wainwright, Investment Bank

What’s next

Investors will be closely watching Aclaris Therapeutics' stock performance in the coming weeks to see if the recent surge can be sustained. The company's next earnings report, expected in late July 2026, will also be a key catalyst for the stock.

The takeaway

The jump in Aclaris Therapeutics' stock price highlights the volatility and speculative nature of the biotech sector. While the company has several promising drug candidates in development, its financial performance and analyst sentiment remain mixed, making the stock a risky investment for all but the most seasoned investors.